Profile data is unavailable for this security.
About the company
Crossject SA is a France-based company that designs and develops medical injection systems. The Company specializes in needle-free, pre-filled, single-use injection systems for intradermal, subcutaneous and intramuscular applications for pharmaceutical companies. Is also has a pipeline and three drugs in the preclinical or clinical phase of research. The Company's products, which are based on well-known injectable drugs (chemicals and biologics), are designed to enhance patients' safety, compliance and comfort. Crossject’s first ZENEO SUPERGENERIC product is expected to reach the market in the year 2015. The Company has industrial partnerships with Hirtenberger and Recipharm.
- Revenue in EUR (TTM)500.00k
- Net income in EUR-9.84m
- Incorporated2001
- Employees110.00
- LocationCrossject SAParc Mazen-Sully6 Rue Pauline KergomardDIJON 21000FranceFRA
- Phone+33 380549850
- Fax+33 148046723
- Websitehttps://www.crossject.com
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Theraclion SA | 1.87m | -4.88m | 16.92m | 30.00 | -- | 2.50 | -- | 9.05 | -0.1362 | -0.1362 | 0.0504 | 0.1481 | 0.1021 | 0.282 | 1.23 | 66,785.00 | -26.65 | -40.08 | -35.36 | -59.96 | 54.21 | 52.19 | -260.94 | -276.13 | 2.50 | -56.17 | 0.2546 | -- | -16.58 | -12.66 | -32.02 | -- | 11.77 | -- |
| Diagnostic Medical Systems SA | 37.53m | 3.02m | 20.10m | 120.00 | 7.23 | 1.11 | 3.70 | 0.5356 | 0.1577 | 0.0283 | 2.17 | 1.03 | 0.7146 | 1.69 | 4.58 | 320,760.70 | 3.97 | -11.14 | 6.98 | -19.52 | 39.49 | 37.79 | 5.55 | -15.54 | 0.8608 | -5.70 | 0.5059 | -- | -4.57 | 5.40 | -44.25 | -- | -- | -- |
| Mauna Kea Technologies SA | 10.90m | -2.17m | 24.27m | 67.00 | -- | -- | 22.56 | 2.23 | -0.0488 | -0.0488 | 0.2449 | -0.3386 | 0.5265 | 2.01 | 6.73 | 194,696.40 | -2.61 | -58.19 | -5.19 | -83.91 | 37.11 | -1.33 | -4.96 | -182.40 | 0.7405 | 29.85 | 2.22 | -- | -2.87 | 2.26 | 16.85 | -- | -27.66 | -- |
| Novacyt SA | 9.18m | -29.50m | 50.26m | 222.00 | -- | 0.4015 | -- | 5.47 | -0.4178 | -0.4191 | 0.13 | 1.77 | 0.0528 | 1.33 | 0.2622 | 41,352.57 | -16.96 | 17.69 | -20.71 | 23.82 | 43.21 | 62.82 | -321.40 | 23.87 | 4.98 | -79.02 | 0.0036 | 0.00 | -77.28 | 13.49 | -269.46 | -- | -13.46 | -- |
| Visiomed Group SA | 12.04m | -3.54m | 56.46m | 73.00 | -- | 2.47 | -- | 4.69 | -0.0119 | -0.0119 | 0.0406 | 0.0776 | 0.3453 | 1.40 | 6.88 | 174,550.70 | -10.44 | -53.01 | -12.11 | -127.09 | 91.46 | 41.03 | -30.24 | -99.08 | 1.70 | -9.31 | 0.2631 | -- | 101.38 | 6.67 | -18.40 | -- | 52.36 | -- |
| Affluent Medical SAS | 0.00 | -15.02m | 62.98m | 52.00 | -- | 1.51 | -- | -- | -0.6596 | -0.6596 | 0.00 | 1.26 | 0.00 | -- | -- | 0.00 | -23.91 | -23.11 | -27.18 | -26.49 | -- | -- | -- | -- | -- | -10.51 | 0.2905 | -- | -- | -- | -2.75 | -- | -11.10 | -- |
| Crossject SA | 500.00k | -9.84m | 75.78m | 110.00 | -- | 12.65 | -- | 151.55 | -0.2624 | -0.2624 | 0.0133 | 0.164 | 0.0162 | 1.39 | 0.1287 | 4,950.50 | -31.96 | -36.80 | -43.49 | -50.03 | -488.40 | -367.56 | -1,968.80 | -2,100.44 | 1.11 | -25.32 | 0.7704 | -- | 4.61 | -- | -3.25 | -- | 9.80 | -- |
| Carmat SA | 895.00k | -54.36m | 110.68m | 177.00 | -- | -- | -- | 123.66 | -2.25 | -2.25 | 0.0369 | -0.3817 | 0.0123 | 1.58 | 0.2029 | 5,000.00 | -74.73 | -76.92 | -89.51 | -93.77 | -3,232.74 | -- | -6,074.19 | -9,203.39 | 2.81 | -14.25 | 1.18 | -- | -84.52 | -- | 13.24 | -- | -10.97 | -- |
| Bastide Le Confort Medical SA | 523.32m | 6.32m | 115.59m | 3.55k | 21.54 | 1.43 | 1.41 | 0.2209 | 0.7299 | 0.772 | 65.57 | 11.02 | 0.7955 | 5.44 | 6.90 | 147,580.70 | 1.84 | 2.49 | 2.66 | 3.52 | 50.54 | 48.82 | 2.31 | 3.05 | 0.811 | 1.92 | 0.8391 | -- | 8.48 | 11.94 | 11.24 | 17.55 | 6.98 | -- |
| Amplitude Surgical SA | 104.05m | 43.23m | 147.90m | 416.00 | 3.42 | 1.56 | 2.70 | 1.42 | 0.9002 | 0.9002 | 2.17 | 1.97 | 0.3955 | 0.5652 | 8.83 | 244,244.10 | 16.21 | -0.3658 | 19.44 | -0.4267 | 79.41 | 78.30 | 40.98 | -1.08 | 1.21 | 0.4163 | 0.5395 | -- | 14.44 | -0.0271 | 993.58 | -- | 7.11 | -- |
| Lumibird SA | 203.56m | 7.13m | 312.29m | 1.05k | 39.05 | 1.61 | 12.76 | 1.53 | 0.3559 | 0.3559 | 9.14 | 8.62 | 0.5238 | 1.09 | 4.05 | 193,497.10 | 1.83 | 3.13 | 2.44 | 3.99 | 61.68 | 61.76 | 3.50 | 5.89 | 1.62 | 2.47 | 0.4287 | 0.00 | 6.60 | 15.12 | -37.23 | -2.47 | 18.34 | -- |
Data as of Apr 18 2024. Currency figures normalised to Crossject SA's reporting currency: Euro EUR
2.02%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| OFI Invest Asset Management SAas of 29 Feb 2024 | 408.94k | 1.12% |
| Tocqueville Finance SAas of 31 Jan 2024 | 151.52k | 0.42% |
| Sunny Asset Management SAas of 27 Mar 2024 | 107.50k | 0.29% |
| Financi�re Arbevel SAas of 30 Dec 2022 | 27.27k | 0.08% |
| Meeschaert Asset Management SAas of 14 Sep 2023 | 20.00k | 0.06% |
| Clay Asset Management SASas of 30 Jun 2023 | 15.00k | 0.04% |
| Optigestion SAas of 31 Dec 2021 | 8.16k | 0.02% |
More ▼
Data from 31 Dec 2021 - 27 Mar 2024Source: FactSet Research Systems Inc.
